Evidence map›Paper›PMID 37060076›Full record

ArticlePediatric rheumatology online journal2023

The feasibility of existing JADAS10 cut-off values in clinical practice: a study of data from The Finnish Rheumatology Quality Register.

M Backström, H Salo, J Kärki, K Aalto, K Rebane, T Levälampi, M-M Grönlund, L Kröger, H Pohjankoski, M Hietanen and 9 more

Abstract read
In one paragraph

Article in Pediatric rheumatology online journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

M BackströmDepartment of Paediatrics, The Wellbeing Services County of Ostrobothnia, Vaasa, Finland. maria.backstrom@ovph.fi.ORCID http://orcid.org/0000-0002-8632-8634
H SaloKnowledge Brokers Department, Finnish Institute for Health and Welfare, Helsinki, Finland.
J KärkiDepartment of Children and Adolescents, Kanta-Häme Central Hospital, Hämeenlinna, Finland.
K AaltoNew Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
K RebaneNew Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
T LevälampiNew Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
M-M GrönlundDepartment of Paediatrics, Turku University Hospital, Turku, Finland.
L KrögerDepartment of Children and Adolescents, Kuopio University Hospital, Kuopio, Finland.
H PohjankoskiDepartment of Children and Adolescents, Päijät-Häme Central Hospital, Lahti, Finland.
M HietanenDepartment of Children and Adolescents, Päijät-Häme Central Hospital, Lahti, Finland.
K KorkattiDepartment of Paediatrics, Central Ostrobothnia Central Hospital, Kokkola, Finland.
L KuusaloCentre for Rheumatology and Clinical Immunology, Division of Medicine, University of Turku and Turku University Hospital, Turku, Finland.
V RantalaihoFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
J HuhtakangasDivision of Rheumatology, Kuopio University Hospital, Kuopio, Finland.
H RelasDepartment of Rheumatology, Inflammation Center, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.
T PääkköDepartment of Internal Medicine, Oulu University Hospital, Oulu, Finland.
E LöyttyniemiDepartment of Biostatistics, University of Turku, Turku, Finland.
T Sokka-IslerUniversity of Eastern Finland, Kuopio and Central Finland Central Hospital, Jyväskylä, Finland.
P VähäsaloPEDEGO Research Unit, University of Oulu, Oulu, Finland.

Funding

Suomen Lääketieteen Säätiö 4947
6 · The paper itself

Abstract

backgroundThe ten-joint juvenile arthritis disease activity score (JADAS10) is designed to measure the level of disease activity in non-systemic juvenile idiopathic arthritis by providing a single numeric score. The clinical JADAS10 (cJADAS10) is a modification of the JADAS10 that excludes erythrocyte sedimentation rate (ESR). Three different sets of JADAS10/cJADAS10 cut-offs for disease activity states have been published, i.e., the Backström, Consolaro, and Trincianti cut-offs. The objective of this study was to investigate the performance of existing JADAS10 cut-offs in real-life settings using patient data from The Finnish Rheumatology Quality Register (FinRheuma).

methodsData were collected from the FinRheuma register. The proportion of patients with an active joint count (AJC) above zero when classified as being in clinically inactive disease (CID) or low disease activity (LDA) groups according to existing JADAS10/cJADAS10 cut-off levels were analyzed.

resultsA significantly larger proportion of the patients classified as being in CID had an AJC > 0 when using the JADAS10/cJADAS10 cut-offs by Trincianti et al. compared to those for the other cut-offs. In the LDA group, a significantly larger proportion of the polyarticular patients (35%/29%) had an AJC of two when Trincianti JADAS10/cJADAS10 cut-offs were used compared with when Backström (11%/10%) and Consolaro (7%/3%) JADAS10/cJADAS10 cut-offs were used.

conclusionsWe found the cut-offs proposed by Consolaro et al. to be the most feasible, since these cut-off levels for CID do not result in the misclassification of active disease as remission, and the proportion of patients with AJC > 1 in the LDA group is lowest using these cut-offs.

Indexed as

Antirheumatic AgentsArthritis, JuvenileRheumatologyFeasibility StudiesFinlandHumansAntirheumatic AgentsDisease activityJuvenile idiopathic arthritisOutcome measures

Identifiers

PMID37060076
PMCPMC10105448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.